{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:03:57Z","timestamp":1793156637464,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Postgraduate Institute of Medical Education and Research","award":["Special Research Grant for MD\/DM Thesis"],"award-info":[{"award-number":["Special Research Grant for MD\/DM Thesis"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00280-023-04546-3","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T08:02:59Z","timestamp":1685520179000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"92","author":[{"given":"Minu","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Bhaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozy","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9071-7651","authenticated-orcid":false,"given":"Amita","family":"Trehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"4546_CR1","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","volume":"381","author":"H Inaba","year":"2013","unstructured":"Inaba H, Greaves M, Mullighan CG (2013) Acute lymphoblastic leukaemia. Lancet (Lond, Engl) 381:1943\u20131955","journal-title":"Lancet (Lond, Engl)"},{"key":"4546_CR2","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH, Carroll WL (2012) Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group. J Clin Oncol 30:1663\u20131669","journal-title":"J Clin Oncol"},{"key":"4546_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/FPC.0b013e328334338f","volume":"20","author":"G Zaza","year":"2010","unstructured":"Zaza G, Cheok M, Krynetskaia N et al (2010) Thiopurine pathway. Pharmacogenet Genom 20:573\u2013574","journal-title":"Pharmacogenet Genom"},{"key":"4546_CR4","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/jnci\/91.23.2001","volume":"91","author":"MV Relling","year":"1999","unstructured":"Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001\u20132008","journal-title":"J Natl Cancer Inst"},{"key":"4546_CR5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/bcp.12226","volume":"77","author":"L Lennard","year":"2014","unstructured":"Lennard L (2014) Implementation of TPMT testing. Br J Clin Pharmacol 77:704\u2013714","journal-title":"Br J Clin Pharmacol"},{"key":"4546_CR6","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1200\/JCO.2014.59.4671","volume":"33","author":"JJ Yang","year":"2015","unstructured":"Yang JJ, Landier W, Yang W et al (2015) Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 33:1235\u20131242","journal-title":"J Clin Oncol"},{"key":"4546_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/FPC.0000000000000453","volume":"32","author":"T Moriyama","year":"2022","unstructured":"Moriyama T, Yang W, Smith C, Pui CH, Evans WE, Relling MV, Bhatia S, Yang JJ (2022) Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia. Pharmacogenet Genom 32:60\u201366","journal-title":"Pharmacogenet Genom"},{"key":"4546_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/FPC.0000000000000449","volume":"32","author":"Q Wang","year":"2022","unstructured":"Wang Q, Mailloux J, Schwarz UI, Kim RB, Wilson A (2022) A novel NUDT15 variant identified in Caucasian TPMT wild type patients with inflammatory bowel disease and azathioprine-related myelotoxicity. Pharmacogenet Genom 32:39\u201341","journal-title":"Pharmacogenet Genom"},{"key":"4546_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2217\/pgs-2019-0177","volume":"21","author":"A Puangpetch","year":"2020","unstructured":"Puangpetch A, Tiyasirichokchai R, Pakakasama S, Wiwattanakul S, Anurathapan U, Hongeng S, Sukasem C (2020) NUDT15 genetic variants are related to thiopurine-induced neutropenia in Thai children with acute lymphoblastic leukemia. Pharmacogenomics 21:403\u2013410","journal-title":"Pharmacogenomics"},{"key":"4546_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00280-018-3732-3","volume":"83","author":"S Khera","year":"2019","unstructured":"Khera S, Trehan A, Bhatia P, Singh M, Bansal D, Varma N (2019) Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 83:341\u2013348","journal-title":"Cancer Chemother Pharmacol"},{"key":"4546_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41390-020-0868-8","volume":"89","author":"DS Wang","year":"2021","unstructured":"Wang DS, Yu CH, Lin CY et al (2021) Childhood acute lymphoblastic leukemia mercaptopurine intolerance is associated with NUDT15 variants. Pediatr Res 89:217\u2013222","journal-title":"Pediatr Res"},{"key":"4546_CR12","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1136\/gutjnl-2016-311921","volume":"66","author":"HS Kim","year":"2017","unstructured":"Kim HS, Cheon JH, Jung ES et al (2017) A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD. Gut 66:1926\u20131935","journal-title":"Gut"},{"key":"4546_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41397-019-0126-9","volume":"20","author":"S Chen","year":"2020","unstructured":"Chen S, Tan WZ, Sutiman N et al (2020) An intronic FTO variant rs16952570 confers protection against thiopurine-induced myelotoxicities in multiethnic Asian IBD patients. Pharmacogenom J 20:505\u2013515","journal-title":"Pharmacogenom J"},{"key":"4546_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/S13063-022-06033-1","author":"N Das","year":"2022","unstructured":"Das N, Banavali S, Bakhshi S et al (2022) Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. Trials. https:\/\/doi.org\/10.1186\/S13063-022-06033-1","journal-title":"Trials"},{"key":"4546_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/MPH.0000000000000206","volume":"36","author":"K Schmiegelow","year":"2014","unstructured":"Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J (2014) Mercaptopurine\/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol 36:503\u2013517","journal-title":"J Pediatr Hematol Oncol"},{"key":"4546_CR16","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1200\/JCO.2011.38.9924","volume":"30","author":"S Bhatia","year":"2012","unstructured":"Bhatia S, Landier W, Shangguan M et al (2012) Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children\u2019s oncology group. J Clin Oncol 30:2094\u20132101","journal-title":"J Clin Oncol"},{"key":"4546_CR17","unstructured":"Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia\u2014PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/10216075\/. Accessed 6 Sep 2022"},{"key":"4546_CR18","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJM198304283081705","volume":"308","author":"S Zimm","year":"1983","unstructured":"Zimm S, Collins JM, Riccardi R, O\u2019Neill D, Narang PK, Chabner B, Poplack DG (1983) Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308:1005\u20131009","journal-title":"N Engl J Med"},{"key":"4546_CR19","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1651-2227.1986.tb10293.x","volume":"75","author":"P Lafolie","year":"1986","unstructured":"Lafolie P, Hayder S, Bjork O, Ahstr\u00f6m L, Liliemark J, Peterson C (1986) Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma. Acta Paediatr Scand 75:797\u2013803","journal-title":"Acta Paediatr Scand"},{"key":"4546_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.5217\/ir.2017.15.3.328","volume":"15","author":"T Sato","year":"2017","unstructured":"Sato T, Takagawa T, Kakuta Y et al (2017) NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases. Intest Res 15:328\u2013337","journal-title":"Intest Res"},{"key":"4546_CR21","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41375-021-01225-1","volume":"35","author":"L Yao","year":"2021","unstructured":"Yao L, Yin H, Hong M, Wang Y, Yu T, Teng Y, Li T, Wu Q (2021) RNA methylation in hematological malignancies and its interactions with other epigenetic modifications. Leukemia 35:1243\u20131257","journal-title":"Leukemia"},{"key":"4546_CR22","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1158\/0008-5472.CAN-19-4044","volume":"80","author":"H Huang","year":"2020","unstructured":"Huang H, Wang Y, Kandpal M et al (2020) FTO-dependent N 6-methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling. Cancer Res 80:3200\u20133214","journal-title":"Cancer Res"},{"key":"4546_CR23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.bbrc.2018.05.175","volume":"502","author":"J Liu","year":"2018","unstructured":"Liu J, Ren D, Du Z, Wang H, Zhang H, Jin Y (2018) m 6 A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression. Biochem Biophys Res Commun 502:456\u2013464","journal-title":"Biochem Biophys Res Commun"},{"key":"4546_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.bbrc.2019.03.093","volume":"512","author":"J Li","year":"2019","unstructured":"Li J, Han Y, Zhang H, Qian Z, Jia W, Gao Y, Zheng H, Li B (2019) The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA. Biochem Biophys Res Commun 512:479\u2013485","journal-title":"Biochem Biophys Res Commun"},{"key":"4546_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ccell.2016.11.017","volume":"31","author":"A Zejuan Li","year":"2017","unstructured":"Zejuan Li A, Weng H, Su R, Jin J, He C, Chen J (2017) FTO plays an oncogenic role in acute myeloid leukemia as a N 6-methyladenosine RNA demethylase accession numbers GSE34184 GSE30285 GSE76414 GSE84944 GSE85008. Cancer Cell 31:127\u2013141","journal-title":"Cancer Cell"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04546-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04546-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04546-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T11:05:01Z","timestamp":1686567901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04546-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4546"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04546-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"assertion":[{"value":"10 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}